Newron Pharmaceuticals SpA is an Italy-based company operating in the medical research sector. It is a biopharmaceutical company focused on the research, development, and commercialization of therapies for disorders of the central and peripheral nervous system (CNS). The Company specializes in neurological and psychiatric diseases, including schizophrenia and Parkinsonâ€™s disease. Its activities include drug discovery, clinical development, regulatory approval processes, and strategic licensing and commercialization partnerships with pharmaceutical companies worldwide. The Company has built a pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization, such as evenamide, safinamide and ralfinamide. Newron Pharmaceuticals SpA operates at global level.

Employees

Sector

Biotechnology & Medical Research

Calendar

09-21 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
26-08-07	CHF 12.30	-2.07%
26-08-06	CHF 12.56	+2.11%
26-08-05	CHF 12.30	+4.24%
26-08-04	CHF 11.80	+0.68%
26-08-03	CHF 11.72	-1.01%

Real-time CBOE EUROPE EQUITIES

More quotes

07-03	Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment	MT
05-05	Edison Is Not Overly Concerned About a Trial Suspension

Market Cap	272M 315M 254M 233M 438M 29.95B 445M 2.98B 1.17B 15.02B 1.18B 1.16B 49.65B	P/E 2026 *	-9.64x	P/E 2027 *	35.4x
Enterprise Value	311M 359M 290M 266M 501M 34.21B 508M 3.41B 1.34B 17.15B 1.35B 1.32B 56.71B	EV / Sales 2026 *	28.7x	EV / Sales 2027 *	6.4x
Free-Float	86.89%	Yield 2026 *	-	Yield 2027 *	-

07-03	Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment	MT
05-05	Edison Is Not Overly Concerned About a Trial Suspension
04-30	US FDA Halts New Patient Enrollment at Newron's Phase 3 Trial for Schizophrenia Treatment	MT
04-29	Newron reports pause of enrollment of new study participants in US centers of ENIGMA-TRS 2 study	RE
04-29	Newron Pharmaceuticals S.p.A. Reports Pause Of Enrollment of New Study Participants In US Centers Of ENIGMA-TRS 2 Study	CI
04-23	Newron Pharmaceuticals S.P.A. Announces Board Appointments	CI
03-24	Newron Pharmaceuticals S.p.A., 2025 Earnings Call, Mar 24, 2026
03-24	Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Newron Pharmaceuticals Swings to FY25 Net Loss; Revenue Down	MT
03-22	Newron Pharmaceuticals S.p.A. Auditor Raises 'Going Concern' Doubt	CI
03-19	Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 finance contract	RE
03-19	Newron Announces Agreement with the European Investment Bank to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract	CI
03-19	Newron Pharmaceuticals Secures EIB Loan Maturity Extension	MT

07-02	Newron Provides Update Following Type A Meeting With the FDA	BU
05-28	Newron Pharmaceuticals to Participate in June Investor Conferences	BU
04-29	Newron Pharmaceuticals S p A : reports a pause in enrollment of new study participants in US centers of ENIGMA-TRS 2 study	PU
04-29	Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study	BU
04-23	Newron announces AGM 2026 results	EQ

07-02	Newron und FDA erörtern nächste Schritte bei Evenamide-Studie
07-02	Newron gibt Update nach Type-A-Meeting mit der FDA
05-12	Newron-CEO: Beide Studien werden fortgesetzt
05-05	Edison ne s'inquiète pas outre mesure de la suspension d'un essai
04-30	Bourse : Schneider, BNP, Stellantis, Unilever, VW… déluge de publications en Europe

Newron Pharmaceuticals S.p.A. Stock CBOE EUROPE EQUITIES

Stocks

0QOI

IT0004147952

Biotechnology & Medical Research

Valuation: Newron Pharmaceuticals S.p.A.

Chart: Newron Pharmaceuticals S.p.A.

Latest news : Newron Pharmaceuticals S.p.A.

Last Transcript: Newron Pharmaceuticals S.p.A.

Press Releases: Newron Pharmaceuticals S.p.A.

News in other languages: Newron Pharmaceuticals S.p.A.

Quotes and Performance

Course Extremes

Managers and Directors: Newron Pharmaceuticals S.p.A.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Market Closed - CBOE EUROPE EQUITIES Other stock markets 11:20:00 2026-08-07 EDT
12.30 ^CHF	-2.07%

1 week	+3.89%
Current month	+3.89%
1 month	+2.67%
3 months	-10.35%
6 months	-34.99%
Current year	-48.32%

Manager	Title	Age	Since
Stefan Weber CEO	Chief Executive Officer	62	2012-05-14
Roberto Galli DFI	Director of Finance/CFO	-	2011-12-31
Filippo Moriggia COO	Chief Operating Officer	-	2021-12-31

Director	Title	Age	Since
Stefan Weber BRD	Director/Board Member	62	2012-05-14
Gillian Dines BRD	Director/Board Member	-	2023-03-31
Margarita Chavez BRD	Director/Board Member	-	2024-04-16

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEWRON PHARMACEUTICALS S.P.A.	-2.07%	0.00%	-	-	315M
LONZA GROUP AG	+0.99%	+1.78%	+4.07%	+16.73%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.98%	+592.14%	43.61B
BEONE MEDICINES AG	+5.60%	+10.21%	+16.76%	+85.72%	39.6B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+33.39%	+8.85%	39.29B
CELLTRION, INC.	+2.21%	+6.75%	+21.31%	+53.37%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+37.75%	+126.84%	16.49B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+6.24%	+18.87%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+78.59%	+30.30%	12.77B
Average	+2.12%	+6.32%	+85.64%	+116.60%	29.39B
Weighted average by Cap.	+2.54%	+6.10%	+104.25%	+140.79%

	2026 *	2027 *
Net sales	10.84M 12.53M 10.12M 9.29M 17.46M 1.19B 17.73M 119M 46.56M 598M 47.05M 46.03M 1.98B	44.83M 51.81M 41.85M 38.4M 72.2M 4.93B 73.29M 491M 193M 2.47B 195M 190M 8.18B
Net income	-31.17M -36.03M -29.1M -26.71M -50.21M -3.43B -50.97M -342M -134M -1.72B -135M -132M -5.69B	5.02M 5.81M 4.69M 4.3M 8.09M 553M 8.21M 55.04M 21.57M 277M 21.79M 21.32M 916M
Net Debt	38.68M 44.71M 36.11M 33.14M 62.3M 4.26B 63.24M 424M 166M 2.13B 168M 164M 7.06B	14.72M 17.01M 13.74M 12.61M 23.7M 1.62B 24.06M 161M 63.2M 812M 63.85M 62.47M 2.68B

1 week	11.5		12.66
1 month	11.32		12.66